BioWorld MedTech

Feb. 29, 2016

Elite French investors pump fresh $55 million into artificial heart

PARIS — To fund its ramp-up to market, artificial heart maker Paris-based Carmat SA raised €50 million ($55 million) through a reserved capital increase put together by a cluster of elite French institutional investors. Read More

Spectranetics hopeful for a stellar year, fueled by Stellarex DCB

OA trials numerous but endpoints tricky as stakeholders search for another way

International Stroke Conference tPA costs and their impact on AIS therapies addressed at meeting

Panel says a heavy hand will impede use of NGS in oncology

Other News to Note

Appointments & Advancements

Keeping you up to date on recent developments in Neurology

Today's news in brief

BioWorld

BioWorld briefs for April 17, 2025.

Today's news in brief

BioWorld MedTech

BioWorld MedTech briefs for April 17, 2025.

ADPD 2025: Novel treatment modalities in neurodegenerative disorders

BioWorld Science

The current treatment strategies for neurodegenerative diseases focus on targeting Aβ in Alzheimer’s disease (AD), α-synuclein aggregates in Parkinson’s disease...

Many US tariffs paused, pharma warned, EU put on notice

BioWorld

The on-again, off-again U.S. tariffs are off again, at least for now, for more than 75 countries that have reached out to the Trump administration to negotiate...

Ouch! Tariffs hit med tech harder than expected

BioWorld MedTech

First quarter earnings reports from Johnson & Johnson and Abbott Laboratories provided some surprising insights into the likely hit med-tech companies will...